Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 12/20 | 0.74 |
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253839 | 0.91 | ICMT (0.69) | ICMTCDC25ACNR2MCL1PLA2G2A | |
| SCHEMBL28370235 | 0.87 | CDC25A (0.73) | ICMTCDC25ACNR1CNR2MCL1 | |
| SCHEMBL10965765 | 0.87 | ICMT (0.71) | ICMTCDC25ACNR2MCL1PLA2G2A | |
| SCHEMBL3667313 | 0.86 | ICMT (0.97) | ICMTCDC25ACNR1 | |
| SCHEMBL11893393 | 0.85 | ICMT (1.00) | ICMTCDC25A | |
| SCHEMBL8086295 | 0.84 | ICMT (0.71) | ICMTCDC25ACNR2 | |
| SCHEMBL13241404 | 0.84 | ICMT (0.67) | ICMTCDC25ACNR1CNR2MCL1 | |
| SCHEMBL8088107 | 0.83 | ICMT (0.70) | ICMTCDC25AMCL1 | |
| SCHEMBL13241409 | 0.83 | ICMT (0.70) | ICMTCDC25AMCL1 | |
| SCHEMBL10181834 | 0.82 | CDC25A (0.58) | ICMTCDC25ACNR1CNR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008117935-A1 | NK CELL ACTIVATING MOLECULES, NK CELLS AND PHARMACEUTICAL COMPOSITONS COMPRISING THE SAME | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2008-10-02 | — | — | WO | disclosed |
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1487822-A2 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| WO-2003076398-A2 | PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
| US-5990319-A | REACTING INDOLYL-3-ACETAMIDE WITH INDOLYL-3-GLYOXYL REAGENT | ELI LILLY AND COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | ICMT 4596/4885CDC25A 56/4885CNR1 1602/4885 |
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | ICMT 4746/4885CDC25A 340/4885CNR1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.